FDA Approves New Schizophrenia Drug, Cobenfy, Developed By Karuna Therapeutics

On September 26, 2024, the Food and Drug Administration (FDA) approved the first new drug to treat schizophrenia in more than 35 years. The drug is branded as Cobenfy. It was developed by Karuna Therapeutics, which was acquired by Bristol Myers Squibb (BMS) in March 2024. Cobenfy is an oral medication (formerly referred to as KarXT) to treat adults diagnosed with schizophrenia. In clinical trials, people who took Cobenfy had reductions in symptoms of schizophrenia without the metabolic changes and movement disorder side effects characteristic of previously approved antipsychotics.

In announcing the FDA approval, BMS also announced the launch of . . .